| 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: The Task Force for diabetes, pre-diabetes, and … F Cosentino, PJ Grant, V Aboyans, CJ Bailey, A Ceriello, V Delgado, ... European heart journal 41 (2), 255-323, 2020 | 5079 | 2020 |
| Cardiorenal end points in a trial of aliskiren for type 2 diabetes HH Parving, BM Brenner, JJV McMurray, D De Zeeuw, SM Haffner, ... New England Journal of Medicine 367 (23), 2204-2213, 2012 | 1690 | 2012 |
| Aliskiren combined with losartan in type 2 diabetes and nephropathy HH Parving, F Persson, JB Lewis, EJ Lewis, NK Hollenberg New England Journal of Medicine 358 (23), 2433-2446, 2008 | 1592 | 2008 |
| Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs … KI Birkeland, ME Jørgensen, B Carstensen, F Persson, HL Gulseth, ... The lancet Diabetes & endocrinology 5 (9), 709-717, 2017 | 393 | 2017 |
| Diagnosis of diabetic kidney disease: state of the art and future perspective F Persson, P Rossing Kidney international supplements 8 (1), 2-7, 2018 | 343 | 2018 |
| Urinary proteomics for early diagnosis in diabetic nephropathy P Zürbig, G Jerums, P Hovind, RJ MacIsaac, H Mischak, SE Nielsen, ... Diabetes 61 (12), 3304-3313, 2012 | 310 | 2012 |
| Diagnosis and prediction of CKD progression by assessment of urinary peptides JP Schanstra, P Zürbig, A Alkhalaf, A Argiles, SJL Bakker, J Beige, ... Journal of the American Society of Nephrology 26 (8), 1999-2010, 2015 | 258 | 2015 |
| Dapagliflozin is associated with lower risk of cardiovascular events and all‐cause mortality in people with type 2 diabetes (CVD‐REAL Nordic) when compared with dipeptidyl … F Persson, T Nyström, ME Jørgensen, B Carstensen, HL Gulseth, ... Diabetes, Obesity and Metabolism 20 (2), 344-351, 2018 | 238 | 2018 |
| Early detection of diabetic kidney disease by urinary proteomics and subsequent intervention with spironolactone to delay progression (PRIORITY): a prospective observational … N Tofte, M Lindhardt, K Adamova, SJL Bakker, J Beige, JWJ Beulens, ... The lancet Diabetes & endocrinology 8 (4), 301-312, 2020 | 227 | 2020 |
| The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics DC Wheeler, BV Stefansson, M Batiushin, O Bilchenko, DZI Cherney, ... Nephrology Dialysis Transplantation 35 (10), 1700-1711, 2020 | 190 | 2020 |
| Renal effects of aliskiren compared with and in combination with irbesartan in patients with type 2 diabetes, hypertension, and albuminuria F Persson, P Rossing, H Reinhard, T Juhl, CDA Stehouwer, C Schalkwijk, ... Diabetes care 32 (10), 1873-1879, 2009 | 189 | 2009 |
| Time course of the antiproteinuric and antihypertensive effects of direct renin inhibition in type 2 diabetes F Persson, P Rossing, KJ Schjoedt, T Juhl, L Tarnow, CDA Stehouwer, ... Kidney international 73 (12), 1419-1425, 2008 | 187 | 2008 |
| Implementation of proteomic biomarkers: making it work H Mischak, JPA Ioannidis, A Argiles, TK Attwood, E Bongcam‐Rudloff, ... European journal of clinical investigation 42 (9), 1027-1036, 2012 | 182 | 2012 |
| Differential effects of dapagliflozin on cardiovascular risk factors at varying degrees of renal function S Petrykiv, CD Sjöström, PJ Greasley, J Xu, F Persson, HJL Heerspink Clinical Journal of the American Society of Nephrology 12 (5), 751-759, 2017 | 179 | 2017 |
| YKL-40, a marker of inflammation and endothelial dysfunction, is elevated in patients with type 1 diabetes and increases with levels of albuminuria CN Rathcke, F Persson, L Tarnow, P Rossing, H Vestergaard Diabetes care 32 (2), 323-328, 2009 | 178 | 2009 |
| A urinary peptide biomarker set predicts worsening of albuminuria in type 2 diabetes mellitus SS Roscioni, D De Zeeuw, ME Hellemons, H Mischak, P Zürbig, ... Diabetologia 56, 259-267, 2013 | 168 | 2013 |
| RETRACTED: Estimating dose-response relationships for vitamin D with coronary heart disease, stroke, and all-cause mortality: observational and Mendelian randomisation analyses E Sofianopoulou, SK Kaptoge, S Afzal, T Jiang, D Gill, TE Gundersen, ... The Lancet Diabetes & Endocrinology 9 (12), 837-846, 2021 | 145 | 2021 |
| Progressive decline in estimated glomerular filtration rate in patients with diabetes after moderate loss in kidney function—even without albuminuria D Vistisen, GS Andersen, A Hulman, F Persson, P Rossing, ... Diabetes Care 42 (10), 1886-1894, 2019 | 136 | 2019 |
| Proteomic prediction and Renin angiotensin aldosterone system Inhibition prevention Of early diabetic nephRopathy in TYpe 2 diabetic patients with normoalbuminuria (PRIORITY … M Lindhardt, F Persson, G Currie, C Pontillo, J Beige, C Delles, ... BMJ open 6 (3), e010310, 2016 | 136 | 2016 |
| Multicentre prospective validation of a urinary peptidome-based classifier for the diagnosis of type 2 diabetic nephropathy J Siwy, JP Schanstra, A Argiles, SJL Bakker, J Beige, P Boucek, K Brand, ... Nephrology Dialysis Transplantation 29 (8), 1563-1570, 2014 | 133 | 2014 |
Peter RossingSteno Diabetes CenterAdresse e-mail validée de dadlnet.dk